Skip to main content

Advertisement

Table 1 Characteristics of non-continuous and continuous rofecoxib users (in the 12 months prior to rofecoxib withdrawal)

From: An observational study of the discrediting of COX-2 NSAIDs in Australia: Vioxx or class effect?

Characteristicc Non-Continuous rofecoxib usersa
(N = 383)
%
Continuous rofecoxib usersb
(N = 181)
%
Χ2, df, p-value
Urban Area 51 50 0.06, 1, 0.81
Manage on Income 81 75 2.96, 1, 0.09
Education (No School) 73 71 0.12, 1, 0.73
Marital Married/De facto 34 35  
  Sep/Divorced 4 6 1.81, 2, 0.40
  Widowed/Single 56 59  
BMI Underweight 2 1  
  Normal 47 43 0.043d
  O/weight 50 56  
Smoker 4 6 0.89, 1, 0.34
Alcohol Non-drinker 69 59  
  Rarely/Low drinker 30 34 0.24d
  Risky/High Risk 1 7  
Exc/V. Good/Good General Health 62 59 0.29, 1, 0.59
Consulted Family Doctor ≥5 Visits 73 77 0.94, 1, 0.33
Hospital Doctor Visit in 12 months 22 24 0.35, 1, 0.56
Specialist Doctor Visit in 12 months 61 51 4.73, 1, 0.03
Ever Reported Arthritis 75 94 31.02, 1, < 0.001
Conditions: Hypertension 45 38 2.62, 1, 0.11
  Depression 6 9 1.14, 1, 0.28
  Anxiety/nervous 7 8 0.18, 1, 0.68
  Asthma 8 14 3.99, 1, 0.05
  Diabetes 11 15 1.55, 1, 0.21
  Bronchitis/Emphysema 6 9 1.92, 1, 0.17
  Osteoporosis 29 34 1.35, 1, 0.25
  Heart Disease 21 30 5.23, 1, 0.02
  Cancer 6 4 0.96, 1, 0.33
  1. a Eight or fewer rofecoxib prescriptions dispensed in 12 months before rofecoxib withdrawal (30 September 2003 to 30 September 2004)
  2. b Nine or more rofecoxib prescriptions dispensed in 12 months before rofecoxib withdrawal
  3. c See methods for details of these self-reported ALSWH variables
  4. d Fisher's exact test used due to small cell sizes, p-value only reported